Matsuzaki K, et al. Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan. Clin Exp Nephrol. 2022;26:316–22.

Article  CAS  PubMed  Google Scholar 

Zan J, et al. Safety evaluation of COVID-19 vaccine in patients with IgA nephropathy or IgA vasculitis nephritis. Kidney Int Rep. 2022;7(6):1435–6.

Article  PubMed  PubMed Central  Google Scholar 

Hui Zhuan Tan et al. (2021) Is COVID-19 vaccination unmasking glomerulonephritis?. Kidney Int 100: 2 469–471.

Radhakrishnan Y, Zand L. New onset glomerular disease post–COVID-19 vaccination: is there a link? Kidney. 2023;4(3):294–6.

Article  Google Scholar 

Canney M, et al. A population-based analysis of the risk of glomerular disease relapse after COVID-19 vaccination. J Am Soc Nephrol. 2022;33(12):2247–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ran E, et al. New-onset crescent IgA nephropathy following the CoronaVac vaccine: a case report. Medicine. 2022;101(33): e30066.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uchida T, et al. Acute exacerbation of immunoglobulin A nephropathy complicated by alveolar hemorrhage after coronavirus disease 2019 vaccination: a case report. Medicin. 2023;102(46): e36091.

Google Scholar 

Sekar A, et al. ANCA glomerulonephritis after the Moderna COVID-19 vaccination. Kidney Int. 2021;100(2):473–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Elio Junior Feghali et al. (2021) De-novo antineutrophil Cytoplasmic Antibody-Associated Vasculitis Following the mRNA-1273(Moderna) Vaccine for COVID-19. Cureus 13: 11 19616

Hakroush S, et al. Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and pauci-immune crescentic glomerulonephritis after Pfizre-BioNTech COVID-19 mRNA vaccination. Front Immunol. 2021;30(12): 762006.

Article  Google Scholar 

Lee M, et al. The nucleotide-sensing Toll-Like Receptor 9/Toll-Like Receptor 7 system is a potential therapeutic target for IgA nephropathy. Kidney Int. 2023;104(5):943–55.

Article  CAS  PubMed  Google Scholar 

Teijaro JR, et al. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21:195–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Richmuth AM, et al. mRNA vaccine delivery using lipid nanoparticles. Deliv. 2016;7(5):319–34.

Article  Google Scholar 

Ota K, et al. Comparison of renal histopathology in three patients with gross hematuria after SARS-CoV-2 vaccination. CEN Case Rep. 2023;12(2):176–83.

Article  PubMed  Google Scholar 

Natale P, et al. Immunosuppressive agents for treating IgA nephropathy. Database Syst Rev. 2020;3:CD003965.

Google Scholar 

Rauen T, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225–36.

Article  CAS  PubMed  Google Scholar 

Yuzawa Y, et al. Evidence-based clinical practice guidelines for IgA nephropathy 2014. Clin Exp Nephrol. 2016;20(4):511–35.

Article  PubMed  PubMed Central  Google Scholar 

Hou F, et al. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy a randomized clinical trial. JAMA Netw Open. 2023;6(2):e2254054.

Article  PubMed  Google Scholar 

Rovin BH, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomized, active-controlled, phase 3 trial. Lancet. 2023;402(10417):2077–90.

Article  CAS  PubMed  Google Scholar 

Bengt C, Fellström at al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomized, placebo-controlled phase 2b trial. Lancet. 2017;389(10084):2117–27.

Article  Google Scholar